{
  "chapter_title": "Business Activities",
  "section_title": "Market Share",
  "description": "Relative position vs competitors, competitive advantages.",
  "questions": [
    {
      "question": "What is the market share of Ion Beam Applications SA compared to its competitors in the KYC and credit risk analysis industry?",
      "queries": [
        {
          "query": "Ion Beam Applications SA market share vs competitors",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "KYC and credit risk analysis industry market share by company",
          "results": [
            {
              "text": "luation method (fair \nvalue and carrying amount). The carrying \namount of these financial assets represents the \nmaximum credit exposure of the Group. Foreign currency risk \nThe Group operates internationally and as such, is exposed to foreign exchange risks arising from \ncommercial transactions (sales and supply \ncontracts), from financial assets and liabilities, and from net investments in non-Eurozone \noperations.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Ion Beam Applications SA competitor analysis",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the competitive advantages of Ion Beam Applications SA in the KYC and credit risk analysis sector?",
      "queries": [
        {
          "query": "competitive advantages Ion Beam Applications SA KYC and credit risk analysis",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "market share drivers for Ion Beam Applications SA",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Ion Beam Applications SA unique selling points",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "How does Ion Beam Applications SA's market position compare to its peers in terms of innovation, product offerings, and service delivery?",
      "queries": [
        {
          "query": "Ion Beam Applications SA market positioning vs competitors",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "innovation leaders in KYC and credit risk analysis industry",
          "results": [
            {
              "text": "a fully end to end solution, that may \nbe supported by further strategic acquisitions \nand a stronger presence in key geographical \nareas like India and China. Principal risks and uncertainties faced by the \ncompany (sections 3:6, 1, 1 to 3 and 3:32, 1, 1 to 3, of the BCAC)\nAPPROACH TO RISK MANAGEMENT\nThe Board of Directors, supported by the \nManagement Team, the Risk Management \nCommittee, and the Audit Committee, oversees \nand manages enterprise risk.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "product and service delivery comparison Ion Beam Applications SA vs competitors",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the key factors influencing Ion Beam Applications SA's market share growth or decline in the KYC and credit risk analysis sector?",
      "queries": [
        {
          "query": "drivers of market share growth for Ion Beam Applications SA",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "factors affecting market share decline Ion Beam Applications SA",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "market trends impacting Ion Beam Applications SA",
          "results": [
            {
              "text": "requiring IBA to adapt to the evolving landscape. Nevertheless, the market continues to expand \non the long term, and this situation has neither \nreduced nor slowed down the interest in E-beam \nand X-ray solutions, but rather prompted IBA \nto further develop and enhance its products offerings \nand customer service. To capture this long-term trend, IBA has developed \na new portfolio of services and end-to-end \nsolutions powered by the iconic Rhodotron. 01\nIndustrial \nsolutions\nThese solutions all",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "How does Ion Beam Applications SA's customer base and sales revenue compare to its competitors in the KYC and credit risk analysis industry?",
      "queries": [
        {
          "query": "Ion Beam Applications SA customer base size vs competitors",
          "results": [
            {
              "text": "cellent sales in our businesses \n(Proton Therapy, Dosimetry, Industrial Solutions \nand RadioPharma Solutions), we are managing an \nincreasingly larger installed base and are, as a result, focusing more on service and upgrades. Patients / Clients\nShareholders\nEmployees\nSociety\nPlanet\n2\nIBA\nCORPORATE BROCHURE 2024",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "sales revenue comparison Ion Beam Applications SA vs competitors",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "market share by customer segment for Ion Beam Applications SA",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    }
  ]
}